Sands Capital Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-19,244
| Closed | -$1.39M | – | 71 |
|
|
2025
Q1 | $1.39M | Buy |
19,244
+1,173
| +6% | +$84K | ﹤0.01% | 73 |
|
|
2024
Q4 | $1.34M | Sell |
18,071
-5,320,024
| -100% | -$372M | ﹤0.01% | 69 |
|
|
2024
Q3 | $352M | Sell |
5,338,095
-310,560
| -5% | -$22.6M | 1.07% | 31 |
|
|
2024
Q2 | $522M | Sell |
5,648,655
-153,897
| -3% | -$13.6M | 1.53% | 25 |
|
|
2024
Q1 | $554M | Sell |
5,802,552
-301,150
| -5% | -$25.3M | 1.55% | 24 |
|
|
2023
Q4 | $465M | Buy |
6,103,702
+1,567,526
| +35% | +$109M | 1.41% | 27 |
|
|
2023
Q3 | $314M | Sell |
4,536,176
-127,037
| -3% | -$10.2M | 1.07% | 32 |
|
|
2023
Q2 | $440M | Sell |
4,663,213
-1,544,611
| -25% | -$134M | 1.37% | 27 |
|
|
2023
Q1 | $514M | Sell |
6,207,824
-1,308,261
| -17% | -$103M | 1.69% | 22 |
|
|
2022
Q4 | $561M | Sell |
7,516,085
-2,889,817
| -28% | -$223M | 2.12% | 18 |
|
|
2022
Q3 | $860M | Sell |
10,405,902
-1,305,885
| -11% | -$126M | 3.23% | 13 |
|
|
2022
Q2 | $1.11B | Buy |
11,711,787
+9,502
| +0.1% | +$984K | 3.86% | 7 |
|
|
2022
Q1 | $1.38B | Sell |
11,702,285
-1,010,762
| -8% | -$113M | 3.17% | 11 |
|
|
2021
Q4 | $1.65B | Sell |
12,713,047
-837,369
| -6% | -$97.7M | 3.06% | 13 |
|
|
2021
Q3 | $1.53B | Buy |
13,550,416
+113,882
| +0.8% | +$13M | 2.56% | 16 |
|
|
2021
Q2 | $1.39B | Buy |
13,436,534
+456,072
| +4% | +$43M | 2.36% | 15 |
|
|
2021
Q1 | $1.09B | Buy |
12,980,462
+1,365,822
| +12% | +$115M | 2.1% | 19 |
|
|
2020
Q4 | $1.06B | Sell |
11,614,640
-448,955
| -4% | -$37.2M | 2.01% | 18 |
|
|
2020
Q3 | $963M | Sell |
12,063,595
-364,615
| -3% | -$28.4M | 2.08% | 14 |
|
|
2020
Q2 | $859M | Sell |
12,428,210
-808,546
| -6% | -$57.5M | 2.08% | 18 |
|
|
2020
Q1 | $832M | Sell |
13,236,756
-4,971,921
| -27% | -$359M | 2.78% | 11 |
|
|
2019
Q4 | $1.42B | Sell |
18,208,677
-3,991,575
| -18% | -$312M | 4.11% | 4 |
|
|
2019
Q3 | $1.63B | Sell |
22,200,252
-303,972
| -1% | -$21.4M | 5.23% | 4 |
|
|
2019
Q2 | $1.39B | Sell |
22,504,224
-578,778
| -3% | -$35M | 4.12% | 6 |
|
|
2019
Q1 | $1.47B | Sell |
23,083,002
-788,976
| -3% | -$45M | 4.54% | 6 |
|
|
2018
Q4 | $1.22B | Sell |
23,871,978
-1,249,920
| -5% | -$63.2M | 4.35% | 6 |
|
|
2018
Q3 | $1.46B | Buy |
25,121,898
+4,369,602
| +21% | +$214M | 4.12% | 7 |
|
|
2018
Q2 | $1.01B | Buy |
20,752,296
+1,185,804
| +6% | +$55.3M | 2.88% | 14 |
|
|
2018
Q1 | $910M | Sell |
19,566,492
-1,301,613
| -6% | -$56.5M | 2.69% | 14 |
|
|
2017
Q4 | $784M | Sell |
20,868,105
-841,200
| -4% | -$30.9M | 2.38% | 15 |
|
|
2017
Q3 | $791M | Sell |
21,709,305
-1,190,220
| -5% | -$45.4M | 2.37% | 16 |
|
|
2017
Q2 | $903M | Sell |
22,899,525
-1,122,084
| -5% | -$41M | 2.71% | 15 |
|
|
2017
Q1 | $753M | Sell |
24,021,609
-960,405
| -4% | -$30.1M | 2.37% | 15 |
|
|
2016
Q4 | $780M | Sell |
24,982,014
-2,124,897
| -8% | -$68.8M | 2.72% | 13 |
|
|
2016
Q3 | $1.09B | Sell |
27,106,911
-1,750,854
| -6% | -$65.9M | 3.21% | 10 |
|
|
2016
Q2 | $959M | Sell |
28,857,765
-1,661,199
| -5% | -$56.8M | 2.97% | 11 |
|
|
2016
Q1 | $897M | Sell |
30,518,964
-2,254,182
| -7% | -$62.2M | 2.65% | 15 |
|
|
2015
Q4 | $863M | Buy |
32,773,146
+24,820,836
| +312% | +$645M | 2.22% | 18 |
|
|
2015
Q3 | $188M | Buy |
+7,952,310
| New | +$192M | 0.53% | 35 |
|
Other funds holding EW
Sands Capital Management's EW Position: Q2 2025 in Review
Sands Capital Management sold out of Edwards Lifesciences (EW) in Q2 2025, closing a stake of 19,244 shares — an estimated $1.39M sold.
Sands Capital Management first reported a position in EW in Q3 2015 and held it in 39 quarters. The position peaked at $1.65B in Q4 2021. 1,259 funds tracked by Wall St. Rank hold EW as of Q2 2025.
- Sands Capital Management reported no remaining Edwards Lifesciences position as of Q2 2025 after selling out during the quarter.
- Sands Capital Management sold 19,244 Edwards Lifesciences shares in Q2 2025, an estimated $1.39M.
- Sands Capital Management first reported a position in Edwards Lifesciences in Q3 2015 and held it in 39 quarters.
- Sands Capital Management's Edwards Lifesciences position peaked at $1.65B in Q4 2021.
- 1,259 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2025.
Based on Sands Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.